These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 21621926

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
    Panousis D, Xepapadakis G, Lagoudianakis E, Karavitis G, Salemis N, Koronakis N, Patsouris E, Koronarchis D, Grosomanidis D, Chryssikos G, Ntasiou P, Kyriakidou V, Athanassiadou AM, Athanassiadou P.
    J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ.
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS, Georgiou G, Sivridis E, Kareli D, Tripsiannis G, Papageorgiou A, Chrisafi S, Kritsi Z, Giatromanolaki A.
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [Abstract] [Full Text] [Related]

  • 8. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA, Carlson DL, Horenstein MG, Osborne MP.
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
    Sosińska-Mielcarek K, Duchnowska R, Winczura P, Badzio A, Majewska H, Lakomy J, Pęksa R, Pieczyńska B, Radecka B, Dębska S, Biernat W, Jassem J.
    Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
    [Abstract] [Full Text] [Related]

  • 14. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL.
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [Abstract] [Full Text] [Related]

  • 15. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M, German Breast Group.
    Breast Cancer Res; 2008 May; 10(2):R30. PubMed ID: 18380893
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A, Margaria E, Chiusa L.
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [Abstract] [Full Text] [Related]

  • 18. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.
    Anticancer Res; 2002 Aug; 22(4):2493-9. PubMed ID: 12174951
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.